Alphamab Oncology(9966)

Description: Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

---

Keywords: Medicine Cancer Clinical Medicine Immune System Oncology Breast Cancer Monoclonal Antibodies Cancer Treatment Antineoplastic Drugs Advanced Solid Tumors Immune Checkpoint Checkpoint Inhibitor Biliary Tract Cancer Pd 1 And Pd L1 Inhibitors Her2 Positive Solid Tumors Ox40

---

Home Page: www.alphamabonc.com

No. 175 Fangzhou Road
Suzhou,
China
Phone: 86 512 6285 0800

---

Officers

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)